EKINOPS S.A. (EPA:EKI)
France · Delayed Price · Currency is EUR 3.160
-0.105 (-3.22%)
Aug 6, 2025, 5:35 PM CET
Sage Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 117.37 | 117.67 | 129.1 | 127.62 | 103.57 | 92.8 | Upgrade | |
Revenue Growth (YoY) | 1.56% | -8.85% | 1.16% | 23.22% | 11.60% | -0.72% | Upgrade |
Cost of Revenue | 53.14 | 53.16 | 61.78 | 60 | 47.1 | 41.68 | Upgrade |
Gross Profit | 64.23 | 64.51 | 67.31 | 67.62 | 56.46 | 51.12 | Upgrade |
Selling, General & Admin | 35.9 | 35.88 | 37.99 | 33.27 | 28.8 | 25.7 | Upgrade |
Research & Development | 21.46 | 22.18 | 24.27 | 25.1 | 24.26 | 21.92 | Upgrade |
Other Operating Expenses | 2.04 | 1.09 | 1.43 | 0.46 | 0.41 | -0.18 | Upgrade |
Operating Expenses | 59.41 | 59.15 | 63.68 | 58.84 | 53.48 | 47.44 | Upgrade |
Operating Income | 4.83 | 5.36 | 3.64 | 8.79 | 2.98 | 3.68 | Upgrade |
Interest Expense | -1.51 | -1.51 | -1.02 | -0.34 | -0.41 | -0.53 | Upgrade |
Currency Exchange Gain (Loss) | -0.31 | -0.31 | 0.14 | 2.13 | 0.68 | -0.77 | Upgrade |
Other Non Operating Income (Expenses) | -1.07 | 0.56 | 0.61 | -0.57 | -0.07 | -0.05 | Upgrade |
EBT Excluding Unusual Items | 1.94 | 4.11 | 3.36 | 10.02 | 3.18 | 2.34 | Upgrade |
Merger & Restructuring Charges | -10.36 | -10.36 | - | - | - | -0.36 | Upgrade |
Other Unusual Items | - | - | - | - | 0.4 | - | Upgrade |
Pretax Income | -8.42 | -6.25 | 3.36 | 10.02 | 3.58 | 1.97 | Upgrade |
Income Tax Expense | 0.55 | 0.7 | -0.27 | -2 | -1.59 | -1.2 | Upgrade |
Earnings From Continuing Operations | -8.97 | -6.95 | 3.63 | 12.02 | 5.17 | 3.17 | Upgrade |
Net Income | -8.97 | -6.95 | 3.63 | 12.02 | 5.17 | 3.17 | Upgrade |
Net Income to Common | -8.97 | -6.95 | 3.63 | 12.02 | 5.17 | 3.17 | Upgrade |
Net Income Growth | - | - | -69.82% | 132.62% | 62.87% | 100.44% | Upgrade |
Shares Outstanding (Basic) | 28 | 27 | 27 | 26 | 26 | 25 | Upgrade |
Shares Outstanding (Diluted) | 28 | 27 | 27 | 27 | 26 | 26 | Upgrade |
Shares Change (YoY) | 6.54% | 0.43% | 1.50% | 1.10% | 2.62% | 7.95% | Upgrade |
EPS (Basic) | -0.33 | -0.26 | 0.14 | 0.46 | 0.20 | 0.13 | Upgrade |
EPS (Diluted) | -0.33 | -0.26 | 0.13 | 0.45 | 0.20 | 0.12 | Upgrade |
EPS Growth | - | - | -71.11% | 125.00% | 66.67% | 73.66% | Upgrade |
Free Cash Flow | 11.62 | 10.86 | 5.5 | 2.22 | 7.46 | 2.92 | Upgrade |
Free Cash Flow Per Share | 0.42 | 0.40 | 0.20 | 0.08 | 0.28 | 0.11 | Upgrade |
Gross Margin | 54.73% | 54.83% | 52.14% | 52.99% | 54.52% | 55.08% | Upgrade |
Operating Margin | 4.11% | 4.56% | 2.82% | 6.88% | 2.88% | 3.97% | Upgrade |
Profit Margin | -7.64% | -5.91% | 2.81% | 9.42% | 4.99% | 3.42% | Upgrade |
Free Cash Flow Margin | 9.90% | 9.23% | 4.26% | 1.74% | 7.20% | 3.15% | Upgrade |
EBITDA | 9.13 | 9.64 | 8.21 | 12.43 | 6.08 | 6.35 | Upgrade |
EBITDA Margin | 7.78% | 8.20% | 6.36% | 9.74% | 5.87% | 6.84% | Upgrade |
D&A For EBITDA | 4.3 | 4.28 | 4.57 | 3.65 | 3.1 | 2.67 | Upgrade |
EBIT | 4.83 | 5.36 | 3.64 | 8.79 | 2.98 | 3.68 | Upgrade |
EBIT Margin | 4.11% | 4.56% | 2.82% | 6.88% | 2.88% | 3.97% | Upgrade |
Advertising Expenses | - | 0.52 | 0.7 | 0.4 | 0.09 | 0.24 | Upgrade |
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.